Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients

A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1

(2017) Patricia Gaule et al.   JAMA Oncology

Weighted false discovery rate controlling procedures for clinical trials

(2016) Yoav Benjamini et al.   BIOSTATISTICS

Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma

(2016) Elizabeth D Thompson et al.   GUT

Tumour CD274 (PD-L1) expression and T cells in colorectal cancer

(2016) Yohei Masugi et al.   GUT

Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system

(2016) Kelly A Schats et al.   HISTOPATHOLOGY

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

(2016) David F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies

(2016) Woo Young Sun et al.   Journal of Translational Medicine

PD-L1 is an independent prognostic predictor in gastric cancer of Western patients

(2016) Christine Böger et al.   Oncotarget

Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers

(2016) Sarah Derks et al.   Oncotarget

PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker

(2016) Lei Guo et al.   SpringerPlus

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade

(2015) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection

(2015) Shohei Eto et al.   Gastric Cancer

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer

(2015) Kurt A. Schalper et al.   JNCI-Journal of the National Cancer Institute

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

(2015) Peter Savas et al.   Nature Reviews Clinical Oncology

PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy

(2015) François Bertucci et al.   Oncotarget

Prognostic and predictive value of PDL1 expression in breast cancer

(2015) Renaud Sabatier et al.   Oncotarget

Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer

(2015) Kurt A. Schalper et al.   JNCI-Journal of the National Cancer Institute

Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors

(2015) Mark Ayers et al.   Journal for ImmunoTherapy of Cancer

Anti program death-1/anti program death-ligand 1 in digestive cancers

(2015) Eléonore de Guillebon   World Journal of Gastrointestinal Oncology

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

CD8-positive T-cell lymphoproliferative disorder associated with Epstein-Barr virus-infected B-cells in a rheumatoid arthritis patient under methotrexate treatment

(2014) Hitoshi Koji et al.   Modern Rheumatology

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Critical role of spatial interaction between CD8+ and Foxp3+ cells in human gastric cancer: the distance matters

(2013) Anita Feichtenbeiner et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Clinical impact of programmed cell death ligand 1 expression in colorectal cancer

(2013) Raoul A. Droeser et al.   EUROPEAN JOURNAL OF CANCER

Programmed death ligand-1 expression in non-small cell lung cancer

(2013) Vamsidhar Velcheti et al.   LABORATORY INVESTIGATION

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

(2013) Charles G. Drake et al.   Nature Reviews Clinical Oncology

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

7th Edition of the AJCC Cancer Staging Manual: Stomach

(2010) Kay Washington   ANNALS OF SURGICAL ONCOLOGY

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing

(2010) Josef Rüschoff et al.   VIRCHOWS ARCHIV

Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype

(2009) S. Ogino et al.   CLINICAL CANCER RESEARCH

Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer

(2008) H E Lee et al.   BRITISH JOURNAL OF CANCER